Management of 80 % Carotid Artery Stenosis

1. Determination of Symptomatic Status

• Patients are classified as symptomatic only when they have experienced an ipsilateral stroke, transient ischemic attack, or retinal ischemia within the preceding 6 months; otherwise they are considered asymptomatic. 1, 2, 3

2. Immediate Medical Therapy for Symptomatic Patients

• Dual antiplatelet therapy (aspirin 81–325 mg + clopidogrel 75 mg daily) for ≥ 21 days is recommended when revascularization is not performed immediately. Class I, Level B (European Society of Cardiology). 4, 3

3. Revascularization Indications and Timing for Symptomatic Patients

• Carotid endarterectomy (CEA) is a Class I indication for symptomatic patients with 80 % stenosis provided the centre’s peri‑operative stroke/death rate is < 6 %. 4, 3
• CEA should be performed within 14 days of symptom onset (ideally within 2 weeks) to achieve maximal benefit. 4, 3
• With medical therapy alone, the 18‑month ipsilateral stroke risk is ≈ 19 % for 70–79 % stenosis and ≈ 28 % for 80–89 % stenosis. 1, 2

4. Procedure Selection for Symptomatic Patients

• In patients of average surgical risk (age < 75 years, no severe comorbidities), CEA is the standard of care. 3
• In high surgical risk patients (e.g., severe pulmonary disease, prior neck surgery/radiation, difficult anatomy), carotid artery stenting (CAS) may be considered as an alternative. 3

5. Contra‑indications to Early Revascularization (first 48 h)

• Revascularization should be avoided within the first 48 hours if any of the following are present: acute carotid occlusion, major persistent neurological deficit, middle‑cerebral‑artery infarction involving > 1⁄3 of the territory, pre‑existing parenchymal hemorrhage, or impaired consciousness. 3

6. Post‑Revascularization Management

• After CAS, continue dual antiplatelet therapy for at least 1 month. 4
• Transition to lifelong single antiplatelet therapy (aspirin 81–325 mg or clopidogrel 75 mg). Class I, Level B (European Society of Cardiology). 4, 3
• Duplex ultrasound surveillance should be performed within the first month after the procedure. 4

7. Management of Asymptomatic Patients

• Optimal medical therapy (OMT) is the cornerstone; routine revascularization is Class III, Level A (not recommended) in the absence of high‑risk plaque features. 4, 3
• OMT includes single antiplatelet therapy (aspirin 75–325 mg or clopidogrel 75 mg daily). 5, 6

8. Surveillance Protocol for Asymptomatic Patients

• Baseline duplex ultrasound at 1 month, followed by repeat at 6 months, then annual surveillance thereafter. Annual surveillance is endorsed by the European Society of Cardiology. 4

9. Criteria for Selective Revascularization in Asymptomatic Patients

• Life expectancy > 5 years. 4, 3
• Institutional peri‑operative stroke/death rate < 3 %. 3
• Presence of high‑risk plaque features, such as:
  
  • Ulcerated or irregular plaque morphology. 1, 2
  • Echolucent (lipid‑rich) plaque on ultrasound. 1, 2
  • Intraplaque hemorrhage on imaging. 1, 2
  • Contralateral carotid occlusion. 3

When revascularization is pursued in asymptomatic patients, *CEA is preferred over CAS** for those at average surgical risk. 3

10. Prognosis and Outcomes

• Atherosclerotic plaque does not regress with medical therapy; the goal is stabilization and prevention of progression. 7
• Statins slow plaque progression (average ≈ 0.03 mm/year reduction in intima‑media thickness). 7
• Modern OMT has reduced the 5‑year stroke risk in asymptomatic 70 % stenosis from ≈ 11 % (historical trials) to ≈ 4.7 % (recent studies). 2, 7
• CEA for symptomatic 80 % stenosis lowers the 5‑year ipsilateral stroke risk from ≈ 28 % to ≈ 6–9 %. 1, 2

11. Pitfalls and Quality‑Control Recommendations

• Do not delay antiplatelet therapy while awaiting imaging or specialist referral in symptomatic patients. (no citation needed – practice point)
• Revascularization should not be performed at centres where peri‑operative complication rates exceed 3 % (asymptomatic) or 6 % (symptomatic), as the net benefit disappears. 3
• Routine revascularization in asymptomatic patients without high‑risk features is contraindicated (Class III, Level A). 4, 3
• Patients should be counseled that plaque will not regress; therapy aims to stabilize plaque and prevent events. 7
• Screen all patients for concomitant coronary and peripheral arterial disease, reflecting the systemic nature of atherosclerosis. 2, 7

Carotid Artery Stenosis Management

Diagnostic Evaluation

• The European Society of Cardiology recommends performing carotid duplex ultrasound as the first-line diagnostic test to assess stenosis severity using the NASCET method or its non-invasive equivalent 8
• The American Heart Association suggests obtaining CTA or MRA when ultrasound findings are inconclusive or when detailed anatomic information is needed for potential revascularization planning, as recommended by the European Heart Journal 8
• The European Heart Journal advises against using the ECST method for stenosis assessment as it is not recommended 8
• A vascular team including a neurologist should assess all symptomatic patients, according to the European Heart Journal 8

Medical Therapy

• The American College of Cardiology recommends initiating aspirin 75-325 mg daily or clopidogrel 75 mg daily for asymptomatic carotid stenosis, as stated in the Journal of Neurointerventional Surgery 9
• For symptomatic carotid stenosis, the European Heart Journal suggests starting dual antiplatelet therapy with aspirin 81-325 mg plus clopidogrel 75 mg for the first 21 days if not undergoing immediate revascularization 8
• The European Heart Journal recommends transitioning to single antiplatelet therapy with either clopidogrel 75 mg daily or aspirin long-term after 21 days 8
• High-intensity statin therapy should be initiated immediately for all patients regardless of baseline lipid levels, as indicated by the European Heart Journal 8

Revascularization Consideration

• The European Heart Journal strongly recommends revascularization for symptomatic patients with stenosis ≥70-99% if perioperative stroke/death risk <6% 8
• Revascularization is reasonable for symptomatic patients with stenosis 50-69% if perioperative risk <6%, according to the European Heart Journal 8
• The European Heart Journal advises against revascularization for symptomatic patients with stenosis <50% 8
• For asymptomatic patients, routine revascularization is not recommended in the absence of high-risk features, particularly if life expectancy <5 years, as stated in the European Heart Journal 8

Surveillance Protocol

• The European Heart Journal recommends establishing a structured imaging schedule, with initial imaging at 1 month post-diagnosis to establish baseline 10
• Follow-up imaging should be performed at 6 months to assess stability and exclude new or contralateral lesions, according to the Journal of Neurointerventional Surgery 11
• Annual surveillance is recommended thereafter to monitor for progression, as indicated by the European Heart Journal 8

Critical Management Pitfalls to Avoid

• The European Heart Journal advises against delaying antiplatelet therapy initiation while awaiting imaging or specialist consultation 8
• Revascularization should not be pursued in asymptomatic patients without high-risk features, as strongly advised against by the European Heart Journal with Level A evidence 8
• Perioperative risk assessment should be accurate, as benefit disappears if surgical complication rates exceed 3% for asymptomatic or 6% for symptomatic patients, according to the European Heart Journal 8